MYOM3 and muscular dystrophy: Taken together, our data suggest that MYOM3 fragments are biomarkers for the detection, evaluation and treatment monitoring of DMD, LGMD2D and potentially for other forms of muscular dystrophy associated with increased turnover of sarcomeric proteins.